HOW MUCH ANXIETY
"There is a common tendency in our day, both
on the part of professional psychologists and laymen,
to look upon anxiety as a negative, destructive,
"abnormal" experience, one which must be fought
and if possible annihilated .... "
0. H. Mowrer'
Since 1950 the literature on anxiety, both
professional and lay, has increased a thousandfold in
the form of articles, symposia, reports and scientific
exhibits. And virtually all of this output reflects a
common presumptiol}-that anxiety is a negative,
nonproductive experience. This viewpoint leads naturally to a discussion of how to combat or eliminate
anxiety.
But anxiety, as Mowrer implies, has its uses.
It can play a positive and constructive role in human
development. Without it neither an individual nor a
society can grow.

Productive vs.
nonproductive anxiety:
a matter of degree
For the physician the difference is not an
academic one. He must distinguish between productive and nonproductive anxiety. And the difference
is often one of degree.
In low levels of anxiety, for example, the individual is alert and sensitive to threats and acquires
an increased ability to cope. Performance is often
improved. 2
But at higher levels of anxiety the opposite is
2
true. The ability to distinguish between the dangerous and the trivial is reduced and often leads to
inappropriate behavior. Apprehension becomes fear.
And coping becomes difficult, if not impossible.

Crossing the
anxiety threshold
The key question for the physician then becomes: Is the degree of anxiety experienced produc-

tive or nonproductive for the individual patient?
And while some patients may require relatively large
amounts of anxiety to perform optimally, for others
lower levels of anxiety may prove unproductive.

Librium®
(chlordiazepoxide
HCI): to help lower
the level of anxiety
When anxiety has reached levels that seriously

IS PRODUCTIVE?
impair performance, reassurance and counseling
may be sufficient for the patient. If not, adjunctive
antianxiety medication may be called for.
Librium (chlordiazepoxide HCl), by quickly
and effectively calming the anxious patient, helps to
lower the level of anxiety. When anxiety has been
reduced to manageable levels, therapy with Librium
should be discontinued.

Librium®(chlordiazepoxide
HCl):an
uncomplicated clinical course
To be truly effective, antianxiety medication
must allay anxiety without complicating the clinical
course. Librium meets this criterion. Librium, when
used in proper dosage, rarely interferes with mental
acuity. Side effects are seldom encountered. And
Librium is used concomitantly with many primary
medications.
For a more detailed discussion of the side
effects, precautions and warnings, please consult the
brief summary of product information on this page.
References: 1. Mowrer OH, quoted in May R:
The Meaning of Anxiety. New York, Ronald Press Co., 1950, pp.
108 ff. 2. Basowitz H et al: Anxiety and Stress. New York, McGrawHill, 1955, pp. 12 ff.
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INTRODUCTION
During my residency at the University of Chicago twenty years ago, I performed the few diagnostic
studies employing radioactive isotopes as a "sideline," spending a couple of hours each day in the
laboratory. Nuclear Medicine since then has grown
into a vast field incorporating in vitro studies, in vivo
procedures, and treatment with radioactive isotopes.
The continued development of new isotopes
is presenting us with new techniques. Some of these
isotopes have such a short half-life that they have
to be produced locally, and their purity and concentration have to be controlled by a radiopharmacist
who has become a team member of all larger nuclear
medicine divisions.
The equipment detecting the radiation emerging
from these isotopes has become much more sophisticated, and the quality of the images produced during
scanning procedures approaches that of radiographs.
But imaging has changed from being a simple
reflection of normal or pathological morphology to a
method of dealing with abnormal physiology. Dynamic computer-assisted scanning of the heart, for
example, can tell us.today whether myocardial damage
is irreversible, and multiple sequential scans can
demonstrate an arteriovenous shunt of the brain.

56

It is not astonishing that in this rapidly progressing field even the expert might lose sight of the latest
developments, and this is the reason why the Department of Radiology of the Medical College of
Virginia felt it would be appropriate to present a
program on Nuclear Medicine during our Annual
Postgraduate Course Series in Williamsburg. We
were fortunate in attracting an outstanding faculty
which agreed to undergo the additional workload of
editing selected papers presented in Williamsburg for
publication in this and the forthcoming issue of the

MCV Quarterly.
I would like to congratulate my colleagues for
their superb contributions to the Quarterly. I would
like to thank Ors. Ghahremani and Sharpe who so
ably organized the Postgraduate Course and express
my special appreciation to Ms. Mary-Parke Johnson,
the Managing Editor of the MCV Quarterly, for her
support and editorial assistance.

KLAUS RANNIGER, M.D.

Professor and Chairman
Department of Radiology

Radiopharmaceutical Production and
Quality Control*
JERRY I. HIRSCH, PHARM. D.

Assistant Professor of Radiology and Pharmacy, Medical College of Virginia, Health Sciences Division oj
Virginia Commonwealth University, Richmond, Virginia

With the development of shorter-lived, organspecific radiophatmaceuticals, much of the manufacture and quality control of these products have
shifted from commercial manufactures to individual
nuclear medicine laboratories. Recognizing this fact,
the Nuclear Regulatory Commission (NRC) is encouraging quality assurance by proposing that "an
authorized physician may permit technicians and
other paramedical personnel to perform the preparation and quality control testing of radiopharmaceuticals ... " (1).
Cohen (2) has catagorized pharmaceutical controls into chemical, biological, and physical. Figure 1
is a diagram of these controls. In each control a
degree of purity is implied and is often determined by
comparison to a standard.

Chemical controls.
A. Radiochemical purity. May be defined as that
portion of the stated radionuclide in the stated
chemical form. This can be assessed in the nuclear
medicine laboratory by several techniques. It is applicable to Tc99m-pertechnetate compounds where
the degree of tag to an organ-specific molecule must
be evaluated.
Radiochemical impurities may be demonstrated
in those images where organs other than the target
organ are visualized due to a free (unbound) radioactive component of a labeled product. Visualization of
thyroid on lung imaging (Fig. 2) or stomach with
kidney (Fig. 3) and bone (Fig. 4) imaging are examples of these. Reagent "kits" labeled with

* Presented by Dr. Hirsch at the Postgraduate Course in Nuclear
. Medicine, February 25, 1975, in Williamsburg, Virginia.
MCV QUARTERLY 11(2):57-69, 1975

radionuclides should be at least 90% bound for optimum organ visualization. The assessment of
binding can be accomplished in the laboratory
by the use of gel filtration and/or thin-layer
chromatographic techniques. Labeled reagent kits
may contain small molecules (free Tc99 mpertechnetate), larger labeled molecules, and a
reduced technetium fraction which is considered
neither free nor bound to an organ-specific molecule.
To determine the percentage of each component in
this three-phase system by employing the gel filtration
technique, 1-2 µl of the material is placed at the top
of a gel column and eluted with a suitable solvent.
Heavy molecules which do not enter the gel meshwork will be eluted first, after the void volume. Light
molecules will follow several milliters later. Reduced
technetium, if present, will bind to the gel and can
be removed by oxidation with 0.1 % H 202. This fraction can be subsequently collected with additional
volumes of solvent. The fractionated volumes are
counted and quantitation of each component may be
determined.
Thin-layer chromatography employs the use of
suitable media strips to which is spotted 5µ1 of the
radioactive material 2.5 cm from the bottom of the
strip. The strip is dried and placed in a developing
tank containing a suitable solvent system (Fig. 5).
The solvent is allowed to ascend the strip until the
front is at approximately 14 cm. Solvent systems
chosen provide for the bound material to remain approximately at the origin (point of application) while
free activity migrates to the level of the solvent front.
Using this method, Rf (reference factor) may be
determined. These factors are ratios of distance
57
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Fig. I-Diagram of the radiopharmaceutical controls.

traveled by the radioactive entities to that traveled
by the solvent front. Labeled molecule Rf are approximately 0-0.1 while that of free species 0.8-1.0. Solvent systems may be single or multiple components
and provide for good separation of labeled molecules
and free ionic species.
Strips are removed from developing tanks, air
dried, and analyzed for quantitation of components
in the sample. Strips may be cut into 1 cm widths and
placed into gamma well counters to determine
presence and, therefore, identity of activity on the
strip. The origin (2.5-3 .5 cm) of acceptable
radiopharmaceuticals contains 90% of the counts. A
radiochromatogram well adapter can be used and is
less time consuming (3). Radioscanchromatographs
can provide this information by producing a graph
with peaks of activity demonstrating location and
quantitation of radioactive components.
Figure 6 is a chromatograph of Tc 99mPolyphosphate® (New England Nuclear) used as the
bone scanning agent in Figure 4. The chromatograph
demonstrates activity at the origin representing

Fig. 3-Tc••m-Renotec (Squibb) kidney image demonstrating
stomach uptake of free Tc••m-pertechnetate. (Image provided
courtesy Dr. H. T. Haden, McGuire VA Hospital, Richmond, Va.)

Tc99m-pertechnetate bound to phosphate complexes,
activity between origin and solvent front demonstrating reduced pertechnetate and/ or labeled metabolized phosphates, and a second but less prominent

R

L

>

'

I
•

Fig. 2-1'"-macroaggregated albumin (Abbott) lung image
demonstrating thyroid uptake of free radioiodine.
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J.C. 8-9-74

J.C. 8-9-74

Fig. 4-Tc••m-Polyphosphate® (New England Nuclear) bone image demonstrating stomach uptake of free Tc99m-pertechnetate.
Increased activity in liver probably associated with a reduced
technetium species in blood pool.
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Reco mmended Chromotography Sol vents
Rf
Pree:arotion

Solvent

BTc

FTc

Tc99m (Sn) DTPA

Acetone

0.0

Butyl acetate

o.o

1.0
0. 8

M.E . K.

0.0

1.0

Methanol, 85%

o.o

0.8

Tc99m - MAA

Methanol, 85%

0.0

0.8

Tc99m - Polyphosphate

Acetone
Butyl acetate

0.0
0.0

1.0
0.8

Renotec *

Butanol : Ethanol : Water
(2 :2: 1)

0. 1

0.7

Tc99m - Sulfur Colloid

Methanol, 85%

0. 1

1. 0

Tc99m (Sn ) Glucoheptonate
·Tc99m - HSA

*Eastman TLC Cellulose H6064 media; all others, Gelman ITLC
Type SG

Fig. 5-Chromatography solvent systems recommended for the
determination of bound (BTc) and free (FTc) components of
technetium-99m kit preparations. Each system provides reproducible Rf values used in the identification and quantitation of each
component.

peak at the solvent front demonstrating free
pertechnetate.
Figure 7 compares the chromatographs ofTc••m_
Polyphosphate® (NEN) to that of Osteoscan® (Proctor and Gamble). Technetium-99m-pertechnetate obtained from a 400 millicuries fission Mo 99 -Tc 99 m
generator. was used to prepare each of the above bone
imaging agents. The Tc••m-Polyphosphate® chromatogram demonstrated 98.5% of the pertechnetate
bound to the phosphate complex. With Osteoscan®,
the chromatograph demonstrated a reduced and/ or
labeled metabolized phosphate component of approximately 40%. The manufacturer claimed that the nitrogen atmosphere in the vial was lost through the
rubber closure with oxidation of the Sn(II) reducing
agent. (Recently the manufacturer has adopted a
butyl rubber closure which has resolved this problem.)
Figure 8 is a chromatograph of Tc••m-SnGlucoheptonate® (NEN). With methyl ethyl ketone
(MEK) solvent, peak activity was found at the
origin corresponding to the bound component. No
free pertechnetate was demonstrated. The manufacturer claimed the material may be subject to colloid formation with some resultant localization of
activity in the liver. The material was chromato-

gramed in a physiologic saline solution demonstrating no colloid at the origin.
B. Carrier amount. May be defined as stable or
long-lived isotopes of the nuclide present at the time
of administration of the radiopharmaceutical. Carrier, if present in large quantities, alters the distribution of the nuclide in vivo or adds to radiation burden
if it is radioactive. Manufacturers prepare compounds that are "carrier-free." This has come to
mean that no other isotope of the nuclide has been intentionally added.
C . Buffer amount. The pH of radiopharmaceuticals should be adjusted to provide for stable
complexes as well as physiologic suitability. Most
radiopharmaceuticals are adjusted in the range of pH
4.0 to 8.8.
D. Total ions concentrations. Radiochemical
solutions after production may contain various
metals or metaloids as contaminants. These contaminants may be imparted from apparatus and reagent
materials even if very pure. Complexation of the
radiochemical with these traces give chemically unstable radioactive solutions. A standard of 80µg / ml
of these ions has been set; however, the current state
of the art is to prepare products with less than
lµg / ml.
Of the potential nonradioactive ionic impurities
present in Tc••m-pertechnetate eluent, aluminum [Al
(III)] has produced the most concern. Toxicology of
Al (III) of potential doses administered appears
minimal (Fig . 9); however, it has been reported to
cause flocculation of Tc 99m-sulfur colloid preparations as well as agglutination of red blood cells during
the labeling process (4). Current NRC standards limit
the presence of this ion to lOµg (fission Mo"") and
20µg (activation Mo"") per milliliter of generator

80
60
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Tc 99 m- POLYPHOSPH ATE
METHANOL 85%

40

u

<{

20

CENTIMETERS

Fig. 6.-Chromatograph ofTc 99 m-Polyphosphate® used to produce
bone image in Figure 4 demonstrates bound, reduced , and free
components of the radiopharmaceutical.
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COMPATIBILITY OF KIT SOURCE AND RADIONUCLIDIC BINDING EFFICIENCY
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40
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30
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1-

>

§

20

BOUND - 58.5%
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REDUCED - 40.0 %

10

FREE - I. 5%
CENTIMETERS
Fig. 7-Comparison of chromatographs obtained after preparation of two commercially available bone imaging agents; Tc"m-Polyphosphate® (New England Nuclear), Tc"m-Osteoscan® (Proctor and Gamble) .

eluent. This represents a more stringent requirement
from a previous 500µg Al (III)/10 millicuries Tc99 mpertechnetate limitation .
To determine at what concentration of Al (Ill)
flocculation of sulfur colloid would occur, Al (III)
solution was prepared by dissolving 99+% aluminum
metal in HCI. Aluminum (lll)-Tc 99 m-pertechnetate
solutions were prepared such that Al (Ill) concentration ranged from lOµg/ml to lOOOµg/ml of Tc 99 mpertechnetate in saline (Fig . 10). A control using Al
(lll) free pertechnetate was also prepared. Technetium-99m-sulfur colloid (Squibb) were prepared
by standard methods incorporating each of the Al
(lll)-Tc99 m-pertechnetate solutions as the radioactive
source. Final sulfur colloid volumes were 8 ml giving
resultant Al (III) concentrations of 0 to 12.50 mg%.
Aluminon reagent (aurin-tricarboxylic acid) test
strips (NEN) were evaluated for suitability in the

detection of Al (Ill) contamination at levels associated with sulfur colloid flocculation (Fig. 11 ).
Colloid aggregation was determined by placing 0.1
ml of each sample on a standard hemocytometer
chamber and observation under light microscopy
(Fig. 12).
Two hundred microcuries (0.2 ml) of each of the
sulfur colloid preparations were injected into 250 g
female Sprague-Dawley rats via a femoral vein. Scintiphotos were obtained using the Searle Radiographies .Pho-Gamma HP camera fitted with a pinhole collimator to demonstrate distribution of the
radiocolloid (Fig . 13).
Preparations of sulfur colloid from 0 to 0.63
mg% Al (III) demonstrated no aggregation . Aluminon test papers demonstrated an increase in the presence of Al (III) with each increase in ion concentration . Scintiphotos of test animals demonstrated

HIRSCH: RADIOPHARMACEUTICAL PRODUCTION
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BINDING EFFICIENCY Tc 99 m-Sn-GLUCOHEPTONATE (N.E.N.)
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Fig. 8-Chromatographs obtained following development of Tc••m-Sn-Glucoheptonate® (New England Nuclear) in two solvent systems.
Upper chromatograph demonstrates absence of free pertechnetate. Lower chromatograph demonstrates absence of colloid.

distribution of radiocolloid to liver with no uptake in
lung. At 0.94 mg% Al (III), some colloid aggregation
was present with minimum uptake of colloid in the
lung of test animal. At 1.56 mg% Al (III), aggregate
size became critical with scintiphotos demonstrating
significant quantities of radiocolloid in lung. Lung
uptake of radiocolloid increased at 3.13 mg% Al (III).

Test materials containing 6.25 mg% and 12.50 mg%
Al (III) demonstrated larger aggregates; however,
these materials were not administered to test animals
because aggregates would be limited to the inside
diameter (254µ) of the 25 G needle.
Liver, lung, and spleen from each test animal
were excized and counted using a Picker well counter.

62

HIRSCH: RADIOPHARMACEUTICAL PRODUCTION

Aluminum Ion Spot Test
Aluminon Reagent Paper

TOXICOLOGY ALUMINUM CONTAMINATION IN
PERTECHNETATE
A.E.C. LIMIT - lOµg./ml. NaTc04

STq
IOpg Al 3/ml.

I. V. LD50 OF ALUMINUM (AS AICl 3) IN MICE IS
79 mg./Kg. (EQUIVALENT TO ABOUT 20 mg.

Control

ALUMINUM/Kg,)

l.V. LD2 OF ALUMINUM (AS AICl 3 ) IN MICE IS
55 mg ./Kg. (EQUIVALENT TO 14 mg. ALUMINUM/Kg.)

Fig. 9-Nuclear Regulatory Commission (AEC) allowable limit
for aluminum ion contamination in Tc99m-pertechnetate. Limit is
within a margin of safety for administration to man.

Ratios of counts for liver: lung and liver: spleen were
calculated (Fig. 14) and demonstrated good correlation with Squibb Institute reports for the control
material. At Al (III) concentration of 0.13 mg% to
0.94 mg%, there was a general increase in liver: lung
with a corresponding general decrease in liver: spleen.
Sulfur colloid used in liver imaging vary in size from
mµ to 1 µ. Up to 15% of the material may normally
localize in bone marrow attributable to the smaller
end of colloid size range. With increasing concentrations of Al (III), smaller colloid may aggregate
providing for more liver localization . Similarly, as the
colloid size continues to increase, more of the
material may localize in spleen, which is capable of
phagocytizing colloid larger than that by liver.
At the critical concentration of 1.56 mg% Al
(Ill), liver: lung was 0.32: 1 demonstrating on a pergram basis three times the activity of radiocolloid in
lung as compared to liver. At 3 .13 mg% Al (III), activity in the lung increased to 16 times that of liver.

~
10
25
50
75
125
250
500
1000

µ.g. Al + 3/ml. Kit* (mg. %)

µ.g. Al+ 3/ml. Tc99m04 (mg. %)

10
25
50
75
125
250
500
1000

(1. 0)
(2.5)
(5 .0)
(7.5)
(12.5)
(25.0)
(50.0)
(100.0)

'

1.25
3.13
6.25
9.38
15.63
31.25
62.50
125.00

(0.13)
(0.3 1)
(0.63)
(0.94)
(1.56)
(3.13)
(6.25)
(12.50)

• FINAL PREPARATION = 8 ml.

Fig. IO-Concentration of aluminum ion in radioactive solutions.
Center panel expresses aluminum concentration present in Tc 99mpertechnetate. Third panel expresses aluminum concentration
present following preparation of sulfur colloid kit.

125pgAl+3/ml.
250pgAl+3/ml.
500pgA1+3 /ml.
1000pgAl+3/ml.
Fig. I I-Change in aluminon spot test with increasing concentration of aluminum ion.

In conclusion, the Aluminon test papers were
adequate in detecting Al (III) concentration, and the
maximum allowable concentration of Al (III) in
Tc 99 m-pertechnetate was found to be 75µg/ml. The
current standard is well within this value.
Biological Controls. The United States Phar~
macopeia (USP) specifications for all parenteral
products includes the absence of viable forms of
bacteria, viruses, yeast, and molds as well as
pyrogenic substances. Therefore, radiopharmaceuticals administered parenterally must also be of this
quality.
A. Sterility. Many of the radiopharmaceuticals
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Tc 99 m - SC

Representative of
0 -0.63mg. 0/oAl+3

0.94mg.0/oAl+3

l.56mg.0/oAl+3

3.13mg.0/oAl+3

6.25 mg.0/oAl+3

12.50mg.0/oAl+3

Fig. 12-Effect of increasing concentration of
aluminum ion on colloid aggregation. Magnification is IOX.

1--1

50)J
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0.13mg. 0/oAl+3

Omg. 0/o A1+3

0.63mg. 0/oAl+3

0.31mg. 0/oAl+3

0.94mg.0/oAl+3 .

3.13mg.0/oAl+3

1.56 mg. 0/o A1+3

Fig. 13-Effect of increasing concentration of aluminum ion on
radiocolloid distribution in rat.
Anterior views obtained with
Searle Radiographies-HP gamma
camera fitted with a pin-hole
collimator. Each image represents
the accumulation of 100,000
counts.
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Effect of Al+ 3 Content in Tc99m - Sulfur Colloid on
Distribution Ratios* in Rat 0 rgans (per gram wt.)

mi;i. % Al+ 3

Liver: Lung

Liver: Spleen

0

4.73:1

1.23:1

o. 13

6.73:1

6.43:1

0.31

5.23:1

4.77:1

0.63

3.46: 1

1. 83:1

0.94

4 . 81:1

1.59:1

1.56

0.32:1

1.16:1

3.13

0.06: 1

0.37:1

* 20 min. post-injection (i.v.)
Fig. 14-Ratios ofliver:lung and liver:spleen counts obtained from
excized rat organs. Ratios are expressed per-gram weight of organ.

used as diagnostic agents in nuclear medicine are intended for parenteral administration . Pharmaceuticals of this type must meet USP requirements
in that they are sterile, apyrogenic, and of acceptable
pH (5).
Methods of sterilization vary and selection is
dependant upon stability of the compound and its
label. Terminal sterilization in an autoclave and
membrane filtration are two of the more commonly
used methods employed to sterilize radiopha rmaceuticals. With each of the above methods,
however, samples must be taken and tested to confirm sterility.
The USP method requires innoculation of the
radiopharmaceutical into fluid thioglycolate and
Soybean-Casein Digest medias. A 7-day incubation
period at 30 to 35°C with fluid thioglycolate and 20 to
25°C with Soybean-Casein Digest without evidence of
viable organisms indicates a sterile preparation. It
becomes apparent that activity of radiopharmaceuticals with short physical half-lives would significantly
decay before the product was approved for clinical
use. Under this circumstance, the dilemma of whether
to administer the preparation may be minimized if
asceptic technique were employed and previous
materials tested after-the-fact demonstrated sterility.
Work by Deland and Wagner (6) has shortened
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the determination of sterility to within acceptable
time for short-lived nuclides. Test materials are innoculated in thioglycolate broth containing C' 4
glucose. Viable organisms, if present, would
metabolize the labeled sugar to C' 4 0 2 which is
detected and recorded, demonstrating the presence of
microbial contamination. This procedure, although
not an official test, has reduced lag time from days to
1-3 hours.
B. Apyrogenicity . Pyrogens of microbial origin,
are mucopolysaccharide molecules present as the
result of bacterial, viral, fungal , or yeast contamination . The substances are heat-stable and therefore
resistant to destruction by terminal sterilization.
When administered by some injection route, they
may produce in man such symptoms as mono-or
biphasic fever, chills, malaise, mild to moderate pain
in the joints, and leukopenia, or other less well-defined
clinical signs, such as apprehension, pallor, and substernal oppression (7). Sensitivity of the human body
to administration of pyrogens by the intrathecal
route is such that the biologic insult of this type increases 4000-fold as compared to the intravenous
route (8).
The USP method for the detection of pyrogens
relies upon rectal temperature change in the pre- to
post-innoculated rabbit. Controls for the test are
stringent and include:
I. Use of healthy, mature rabbits each weighing
not less than 1.5 kg that have maintained this
weight for one week.
2. Control temperature of each rabbit used does
not vary by more than l °C from each other.
No animal may be used with a control
temperature exceeding 39.8°C.
3. Animals must be housed individually, free
from excitement, in an environmental temperature that does not vary by more than
± 3°C.
4. Animals may not be used more than once
every 48 hours.
5. Animals may not be used before 2 weeks having been given a test sample that was
pyrogenic.
6. Animals not used for pyrogen testing during a
14-day period must be sham tested 1-3 days
before use.
7. Test material administered may not exceed 10
ml.
Test material is injected into the marginal ear
vein of three animals. Rectal temperatures are
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recorded at hourly intervals for three hours post injection. If none of the test animals show an individual
temperature rise of 0.6°C or more above its control
temperature and ifthe sum of the temperature rises in
all three animals does not exceed l.4°C, the test
material meets the requirement of apyrogenicity. If
the above criteria are not met, the test must be
repeated with five rabbits. If not more than three of
the eight rabbits show temperature rises of 0.6°C or
more and if the sum of the eight temperature rises
does not exceed 3.7°C, the product under test meets
the requirement for apyrogenicity.
Pyrogen testing by the USP method is difficult,
time consuming, and generally not amenable to small
laboratories. Cooper et al (9), have introduced an in
vitro test based on the detection of endotoxin
through gelation of Limulus polyphemus lysate
prepared from blood amebocytes. Test results may be
obtained in 1 hour which represents time saved with
respect to short-lived nuclides. This test is significantly more sensitive than the official test; however, it
is subject to false positive results if the preparation to
be tested contains Ca (II). The problems of adopting
a more sensitive test must be justified in view of the
fact that no documentation exists of pyrexia following administration of materials found apyrogenic by
the USP test. The question of how sensitive pyrogen
testing must be deserves further investigation.
C. Safety. With the administration of pharmaceuticals in radioactive form, safety includes
radiation-absorbed doses received by target and nontarget organs that are within acceptable limits. The
product must also be nontoxic in doses administered
with respect to formed cells in blood as well as organs
to which the material will be distributed.
D. Affinity. Radioactive compounds used in
organ imaging localize by various physiological
mechanisms . Control of the physiochemical
characteristics of the radiopharmaceutical are needed
to assure affinity of the product for target organs.
Soloway and Davis {I 0) reviewed radiopharmaceuticals currently used for organ imaging and
have catagorized their biological basis for localization . In vitro quality control testing is essential to
predetermine that organs of interest will be
visualized. Poor affinity demonstrated by suboptimal
images must frequently be repeated, therefore, necessitating subsequent dosing with radionuclides and increased radiation burden to patients.
Perfusion lung imaging is dependant upon blood
flow to that organ with capillary and terminal

arteriolar blockage by radiolabeled particles. Particles for this purpose must be larger than that of red
blood cells (7µ) to prevent arterial distribution after
intravenous administration . To avoid an unnecessarily long, effective half-life in lung, as well as optimum patient safety, particles should be limited in
size to 50µ. Particle size determination can be easily
accomplished in the laboratory using light
microscopy as a routine check.
Images of liver and spleen are dependant upon
blood flow to these organs with phagocytosis of
radiocolloid by reticuloendothelial cells. Colloid of
0.6µ and 1.0µ are necessary for localization in liver
and spleen respectively. Although colloid may not be
visualized by light microscopy, the test serves as a
negative check for aggregates so large that they might
localize in lung.
Radioactive materials have been used to
delineate special anatomic or biochemical compartments. Labeled serum albumin has been used in the
past for cisternography and currently for blood pool
imaging. Care must be taken not to denature the
protein by excessive labeling or chemical manipulation.
Stannous chloride [Sn(II)] has become a useful
reducing agent in the preparation of technetiumlabeled radiopharmaceuticals. Yano et al (11), in
studies with the bone imaging agent Tc99 m-Sn-EHDP,
found optimum molar ratio of Sn (II):EHDP for
greater bone localization and rapid soft tissue
clearance. They reported the importance in the order
of combination of EHDP, Sn (II) and Tc99mpertechnetate such that poor formulation resulted in
radiocolloid formation with localization in liver.
Poor localization of other technetium products with
significant uptake in thyroid has been noted when
stannic chloride [Sn(III)] forms on crystal surfaces of
the reducing agent.
Physical Controls.
A. Radioactive concentration. Refers to the activity concentration of the product w_ith respect to activity per unit volume. Activity concentration can be
easily determined using a dose calibrator. This instrument has an overall accuracy of 5% and is designed to
quantitate many of the more commonly used
radionuclides.
B. Radioactive purity. This term should be discontinued in favor of the more accurate term
"radionuclide purity." It may be defined as that
proportion of the total activity that is present as the
stated radionuclide.
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The NRC limit for Mogg contamination has been
set at I microcurie Mogg per millicuries Tcggm_pertechnetate and 5 microcuries per dose of Tcggm_
pertechnetate. On a milligram basis the amount of
Mo 9 g necessary for a lethal dose or LD 50 dose
in test animals is large as compared to what can
be eluted from an intact generator system (Fig. 15).
However, on an equal activity basis using the MIRO
system (12, 13), radiation burden from Mogg is 35
times greater as compared to Tcggm. It has also been
demonstrated that parent Mogg produced by neutron
activation of Mog 8 results in Cs 134 contamination.
Radioactive contaminants of Mo 99 -Tc 9 gm
generator systems may be detected radiometrically.
Molybdenum-99 emits 740 and 780 kev gammas as
well as other less energetic photons. A 4 mm lead
shield adapter inserted in the ion chamber of the dose
calibrator would absorb all but 0.0002% of Tc 99 m
gamma (140 kev) and 50% of Mogg gamma (14). It is
fortuitous that Mo 99 activity can be read directly on
the Tc 9gm setting when the pertechnetate source is
placed in the lead adapter. The method allows for
quantitation of the Mogg activity which should not
exceed 0.1 % of the Tc 99 m activity. Cesium-134 emits
605 and 796 kev gammas which penetrate the 4 mm
lead shield and will be quantitated with the Mogg
reading.
In-House Preparation of Radiopharmaceuticals.

Present day practice of nuclear medicine relies
upon readily available organ-specific radiopharmaceuticals. Exhaustive research of natural and manmade radionuclides has resulted in a handful that
demonstrate organ specificity with patient safety. As
a result, research has been directed toward the labeling of molecules with radionuclides of near-ideal
properties for organ selectivity. Technetium-99m
having suitable physical, chemical, and biological
properties enjoys an active role in organ imaging.
Since 1961, many Tcg9m_labeled compounds have
been introduced which have broadened the
diagnostic capabilities of nuclear medicine and/ or
improved radiation burden as compared to
previously used radionuclides.
Much of this research has resulted in the commercial availability of kit preparations where simple asceptic techniques are employed to produce the
desired Tcggm radiopharmaceutical. With the commercial availability of Mogg-Tcggm generators, daily
delivery, or MEK extraction techniques, a continuous supply of Tc 99 m-pertechnetate is at hand for

Toxicology of Radionuclidic Impurities in Pertechnetate

Mo99

9lln

NRC Limit - 1 µCi Mo99 / mCi Tc
99
99m
5 µCi Mo / dose Tc
I . P. lethal dose of Mo (as No 2 MoO 4 ) in rote is about

114 - 117 mg . Mo/ Kg.
I. V. LD 50 of Mo (as Na 2 MoO 4 ) in mice is about 248 mg ./ Kg.

(equivalent to 116 mg . Mo/ Kg,)
No effect dose in mice is obout 28 mg. / Kg .
Cs 134
NRC Limit - 20µCi (total body burden)

Fig. 15-Nuclear Regulatory Commission maximum allowable
limits for radionuclidic impurities in Tc••m-pertechnetate.

the preparation of kits. The commercial availability
of these tools has been a boon to many institutions
which might not be able to provide this diagnostic service. This availability, however, is not without cost,
and newer formulations with clinical merit may
take months before they become commercially
available, thereby limiting diagnostic studies to current available preparation.
Radiopharmaceutical scientists (radiopharmacist, radiochemist) have paralleled the growth of
nuclear medicine consultants by providing efficacious
radiopharmaceutical diagnostic agents. In-house
preparation of radiopharmaceuticals by these individuals have allowed for the availability of newer
agents in nuclear medicine practice. Institutions
preparing radiopharmaceuticals are increasing, and
those without this technical capability may benefit
under a cost-sharing program (15).
Several formulations are available for the
preparation of the more routinely used imaging
agents. The following are currently used at the
Medical College of Virginia Hospitals. Drug-adverse
reactions have not been reported for any of the
products since clinical initiation.
PREPARATION OF Tc99M-SULFUR COLLOID KIT (16)
Solution A:
To 100 ml of Sterile Distilled Water add:
l. 400 mg Sodium Thiosulfate
2. 750 mg Gelatin
3. 850 mg Potassium Monohydrogen Phosphate (Dibasic)
4. 200 mg Disodium Edetate
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Stir and warm the mixture gently to dissolve the
gelatin. After solution is complete, pipette exactly 3 ml of the solution into each 30 ml serum
vials. Seal the vials with rubber closures and
aluminum caps (twice boiled in sterile distilled
water for not less than 30 minutes and autoclaved, wrapped in aluminum foil) and autoclave
Solution A for 15 minutes at 20 PSIG pressure.

PREPARATION OF Tc99M-LABELED HUMAN SERUM
ALBUMIN ( 17)
Materials:

I.

Solution B:
Sterilize 1-3 ml of exactly 0.5N HCl solution in
serum vials by autoclaving for 15 minutes at 20
PSIG pressure.
II.
Solution C:
To 100 ml Sterile Distilled Water add:
1. 1.20 g Sodium Hydroxide pellets
2. 2.8 g Sodium monohydrogen phosphate
Mix well until solution is complete. Do not
autoclave. Sterilize by filtration using 0.22µ
membrane filter.

III.

Procedure:

I.

PREPARATION OF Tc99M MAA KIT (16)
A. Prepare Albumin Sodium Acetate solution
in distilled water such that it contains 10
mg/ml of HSA, 100 mg/ ml of Sodium
Acetate. Sterilize by membrane filtration
(0.22µ size).
B. Prepare Stannous Chloride solution in IN
HCl such that it contains 5 mg/ml of stannous chloride. Sterilize by membrane filtration (0.22µ size).
C. To an empty sterile serum vial containing a
small magnetic stirrer mix 5 ml of Solution A
with 19 ml of Sterile Water for Injection.
Mix well. Add I ml of Solution B. The pH
should be approximately 5.5 .
D. Macroaggregate the Albumin in the above
solution in a water bath at 80°C± l for 12
minutes with stirring.
E. Cool and mix the aggregates well. Each ml
of this preparation now contains:
I. 2 mg HSA as aggregates (denatured)
2. 200µg Stannous Chloride as hydroxide
3. 20 mg Sodium Acetate as buffer
F. Transfer under aseptic conditions 1 ml each
of this solution to presterilized empty serum
vials and store under refrigeration.

Kit (consists of 3 sterile pyrogen-free vials).
Vial "A"-20 ml vial containing 0.85 ml
of IN HCL with two I-inch lengths of Zr
wire inserted through the diaphragm.
Vial "B"-5 ml containing approximately
I ml of HSA 25%.
Vial "C"-5 ml vial containing approximately 2 ml of Sodium Bicarbonate 3.75%
and Sodium Hydroxide 2.0% in sterile
pyrogen-free water for injection.
Lead pig (for housing 200 ml vial during
procedure).
D.C. power source with external leads
adapted with alligator clips capable of
providing 100 milliamps constant current
at 3-5 volts.

Place vial "A" in lead pig; electrically insulate the top of the container by covering
top of lead pig and aluminum band with
masking tape. Rubber diaphragm is left exposed.
II. To vial "A" aseptically add 5.5 ml of
pertechnetate in normal saline (oxident
free). Remove 5.5 ml air.
III. To vial "A" aseptically add 0.1 ml ofHSA
from vial "B" using a 1 ml TB syringe
adapted with a 21 G needle. Flush syringe
several times and remove 0.1 ml of air.
IV. Immediately connect electrodes to power
supply leads by means of alligator clips.
V.
Invert vial allowing contents of vial to
come in contact with both electrodes.
VI. Using circular motion gently agitate the inverted vial. Pass 100 milliamps of current
for exactly 42 seconds; continue to agitate
vial inverted position for an additional 15
seconds after electrolysis is completed.
VII . Remove leads from electrodes, reinvert vial
to upright position and allow vial "A" to
incubate at room temperature for at least
30 minutes.
VIII. Add to vial "A" 1.2 ml of vial "C" .
Remove an equivalent amount of air.
IX. Pass the product through a 0.22µ
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membrane filter and collect in a sterile
empty vial.

8. ATKINS E: Pathogenesis of fever. Physiol Rev 40:580-646,
1960.

Radiopharmaceuticals, whether prepared inhouse or obtained commercially, should be subjected
to quality control testing. If the limitations of image
interpretations are instrumentation, technique, adequate patient history, and radiopharmaceutical
quality, equal attention must be payed to all.

9. COOPER JF, LEVIN J, WAGNER HN JR: New, rapid, in-vitro
test for pyrogen in short-lived radiopharmaceuticals,
abstracted. J Nucl Med 11:310, 1970.
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Interpretation of Cerebral Dynamic Perfusion
Studies*
FRANK H. DELAND, M.D.

Professor of Radiation Medicine, University of Kentucky, Lexington, Kentucky

A review of the literature for the preceding 20
years revea!S that by radionuclide static imaging there
has been little improvement in the detection rate of
cerebral lesions (l-5). The overall accuracy of brain
scans has been reported from 81 % to 84%. For
glioblastoma multiforme and meningioma, the detection rate is 90%-95%; for low-grade astrocytoma, 55%;
and for ischemic strokes, from 10% to 50% depending
on the elapsed time from the onset of symptoms. An
aneurysm must be at least 2.5 cm in diameter and an
arteriovenous malformation 3-4 cm in diameter
before the information content is adequate for detection. In patients with transient ischemic attacks,
static imaging has been unrewarding (6, 7). Why has
there been little improvement in the detection of
cerebral lesions by static imaging in spite of improved
instrumentation and techniques? Visualization of abnormalities depends on a concentration of radioactivity that is greater in the lesion than in the surrounding tissue, and the mechanisms for nuclide
concentration are similar for nearly all of the agents
that have been used during the past 20 years. With
few exceptions the brain-imaging radiopharmaceuticals are not target specific but depend on the nonspecific changes in vascular wall integrity (for example, dedifferentiation or focal increased intravascular
volume, or shunts).
There are a number of lesions that may not be
apparent on static images, which include early
cerebral infarctions, early subdural hematomas, concussion, arteriovenous malformations of less than
critical size for visualization, and neoplasms that are

* Presented by Dr. DeLand at the Postgraduate Course in
Nuclear Medicine, February 25, 1975, in Williamsburg, Virginia.
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not sufficiently vascular or the vascular component is
not sufficiently dedifferentiated to contribute to a
preferential concentration of radioactivity. If
radioactivity does concentrate in a lesion, the
dynamic vascular character of the pathology has not
been revealed without the appropriate study. During
the first passage of the radiopharmaceutical, rapid sequential radionuclide images provide valuable information on the dynamics of the vasculature. Rapid
imaging increases the sensitivity of the total study
because an increase, decrease, or no change in the
blood flow as reflected by the radiopharmaceutical,
has diagnostic meaning when correlated with the
static images. Correlations are made with both abnormal and normal scans, and the normal scan may
provide diagnostic information relative to the
character of the dynamic flow studies.
Technique. In order to obtain radionuclide images that provide the required information, precise
attention must be given to the technique used in the
study. The radionuclide bolus, method of intravenous injection, route of administration, patient
position, and shielding-each must be given consideration.
Since the radionuclide bolus must transverse
more than a meter of vascular channels, mix with
blood from the inferior vena cava in the right heart,
pass through the pulmonary capillary bed, return to
the heart, and then be transported to the brain, a
"tight" bolus is required; that is, less than l one ml.
Two administrative techniques of the radionuclide
bolus are commonly used: the Oldendorf technique
(8) and the saline flush (9). Details of these
procedures can be found in the original articles.
Most commonly, intravenous materials are adMCV QUARTERLY 11(2): 70-74, 1975
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Fig. IA-Early phases of normal dynamic flow (vertex).
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Fig. 18-Venous and recirculatory phases of normal dynamic
flow .

ministered in the veins of the antecubital fossa. It is
imperative that the medial basilic vein be used
whenever possible because this is the most direct
route to the axillary vein. Injection into the lateral
cephalic vein may result in: 1) delay and lengthening
of the bolus because of the narrower caliber of the
vessel and the right angle junction with the axillary
vein, and 2) fractionation of the bolus because of
anastamotic channels and the right angle junction
(10). The Valsalva maneuver may also contribute to
poor bolus characteristic.
Adequate shielding of the chest and shoulders
with lead-impregnated drapes minimizes undesirable
activity from the heart and great vessels. During the

Fig. 2-Nuclear angiography on 65-year-old patient being
evaluated for seizures.

first passage of the radionuclide bolus through the
head, unwanted activity in the scalp can be
eliminated by compression with a blood pressure cuff
at the level of the external occipital protuberance and
the forehead. When the cuff is inflated to above
systolic pressure, the amount of radioactivity
detected during the first transit is reduced about 15%
to 30% (11).
We use the vertex projection as the position of
choice for routine cerebral dynamic perfusion
studies. This projection will provide data on the cortical distribution of most of the anterior cerebral
artery, a portion of the posterior cerebral artery, and
a splay of the middle cerebral artery. Not only is a
greater area of cortex visualized, but a spread of the
middle cerebral branches also provides greater sensitivity for the detection of partial decreases in blood
flow. Other projections are used when the clinical information dictates, particularly in patients with
suspected subdural hematomas.
Cases. Figure IA illustrates the early phases of a
normal dynamic flow (vertex). At 10.5 seconds after
intravenous administration of 99mTc04 , the activity is
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Fig. 4-Nuclear angiography on 14-year-old drowning victim.
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of seizures. The primary drainage from the superior
sagittal sinus is by the right transverse sinus with no
venous structures observed on the left side. Although
asymmetrical transverse sinus drainage is frequently
encountered, displacement of the torcular Herophili
to the right indicates an abnormality that originated
in utero or shortly after birth. The interpretation was
a left infratentorial fossa mass that displaced the
venous structures to the right. Since the patient had
been asymptomatic for 65 years, we concluded that it
probably was a large arachnoid cyst. Cisternography
confirmed the diagnosis.

TIME IN SECONDS
Fig. 3-Dynamic study on patient with left cortical lesion.

first noted in the head; at 12 seconds distribution can
be observed in branches of the middle cerebral artery
and early filling of the anterior and posterior cerebral
arterial areas; further distribution in all three major
cerebral arterial regions is demonstrated; and at the
end of the early circulation, the cerebral cortex is perfused and activity is beginning to drain into the
superior sagittal sinus. Figure l B illustrates the
"venous" and recirculatory phases. Venous drainage
is noted throughout the sequence. Demarcated areas
of persistent activity are found in the superior sagittal
sinus, torcular Herophili, and the bilateral jugular
bulbs (36-second frame).
Figure 2 illustrates the information that can be
obtained from a dynamic study. The sequence was
performed from the posterior projection. The patient,
65 years old, was being evaluated for the recent onset

10.5 SEC

12 .0 SEC

13 .5 SEC

000039
15 . 0 S.EC

16.5 SEC

Fig. 5-Nuclear angiography on patient with head trauma.
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Fig. 6-Diminished flow of left middle cerebral artery in patient
with right hemiparesis.

Correlation of the sequential concentration of
activity in a lesion with the sequential distribution of
activity in the normal brain provides information on
the type of pathology. For eight years a young college
student had had muscular twitching of the right
hand, usually precipitated by physical stress. Static
radionuclide images revealed a left cortical lesion,
oriented with the rolandic sulcus, in the distribution
of the rolandic branch of the left middle cerebral
artery. The dynamic study (Fig 3) presented the
characteristics of a large rapid arteriovenous shunt.
Circumscribed radioactivity was first observed in the
left mid-hemisphere nine seconds after administration of the radiopharmaceutical. By the 12-second
frame, activity was heavily and focally concentrated

lQ. 5 SEC

12.0 SEC

13 ..S SEC

9972
15.Q SEC

16.5 SEC.

Fig. ?-Diminished flow to left hemisphere in patient with right
h€:.1lliparesis.

•~

"·· +;

8906

21 sec
31.5 sec
Fig. 8-Dynamic study on patient with suspected arteriovenous
malformation.

in the left hemisphere, and early distribution to right
cortical area was present.
Within 1 \/2 seconds (13.5-second frame), there
was venous drainage through the superior sagittal
sinus. Since the 1.5-second interval was too short a
period to attribute the venous drainage to the right
hemispheric circulation, only a vascular shunt would
produce this sequence of events. The diagnosis was a
rapid arteriovenous malformation that originated
from branches of the left middle cerebral artery and
drained into the superior sagittal sinus. Contrast
angiography demonstrated the arteriovenous malformation and also revealed that there was a "steal"
from the right internal carotid blood supply by way
of the anterior communicating artery.
A 14-year-old boy nearly drowned and subsequently developed pneumonia and pulmonary
abscesses. He became somnolent, and an electroencephalogram demonstrated diffuse encephalopathy.
In the radionuclide angiogram there was no perfusion through the right middle cerebral artery with
little evidence of collateral circulation (Fig 4).
Angiography revealed obstruction of the internal
carotid at the base of the skull. The absence of flow
and collateral circulation suggested cerebral edema
which was demonstrated by autopsy examination.
Cerebral radionuclide angiography has been
particularly helpful in the detection of concussion
and contusion with associated vasospasm. For example, a 40-year-old man received head trauma with
contusion of the scalp on the left side. The static im-
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ages demonstrated increased peripheral activity along
the left side that could have been a subdural
hematoma or superficial scalp trauma. The dynamic
study revealed irregular decreased perfusion of the
right middle cerebral artery (Fig 5). On the basis of
the increased superficial radioactivity on the left and
the decreased perfusion on the right, the interpretation was contracoup concussion or contusion with
vasospasm. Subsequent follow-up examinations did
not demonstrate evidence of subdural hematoma,
and the patient recovered completely.
Radionuclide angiography has proven most
useful in patients with cerebrovascular diseases.
Most of our patients with strokes usually are examined within several days after the onset of symptoms. Although static studies are almost invariably
negative, the dynamic studies are usually positive if
the site of the infarction is cortical. Figure 6 illustrates diminished flow of the left middle cerebral
artery in a patient with a right hemiparesis. In addition to the localization of the decreased blood flow,
collateral flow can frequently be evaluated and furnish prognostic information. In this patient there is
little evidence of collateral blood flow to the left
hemisphere. The probability of his regaining function
from this hemisphere is poor, which was borne out by
his subsequent course. In contrast, Figure 7 illustrates another patient with a right hemiparesis and
decreased flow to the left hemisphere. In the sequential frames there is collateral blood flow to the left
hemisphere, and this patient's prognosis is better. We
have found a good correlation between the status of
collateral blood flow (determined within a week after
the stroke) and recovery of function in the affected
side.
As stated earlier, increased, decreased, or no
change in perfusion does contribute to the differential
evidence in the diagnosis of cerebral lesions. For example, a 40-year-old man developed right-sided
symptoms over a period of several months. The static
images revealed an area of increased activity of the
left cerebral hemisphere, limited to the cortex, and
correlated with the configuration of the rolandic
branch of the left-middle cerebral artery. From the
static images the lesion was interpreted as a possible
arteriovenous malformation, or as a lesser possibility,
a progressive stroke. The dynamic study (Fig 8)
demonstrated early concentration of radioactivity in
the correct location that persisted through the
dynamic sequence and did not "wash out." This
evidence suggested a neoplasm, probably an en-

plaque meningioma that was found at subsequent
surgery.
The pos1t10n of cerebral radionuclide
angiography has been well established. In our experience, 75%-85% of diagnosis from brain imaging
is based on the dynamic studies. Improved techniques
and continued experience with nuclide angiography
can be expected to advance the diagnosis of central
nervous system lesions.
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Diagnostic Use of Radionuclides in Diseases of
the Thyroid*
ALTON R. SHARPE, JR., M.D.
Professor of Radiology and Medicine, and Chairman, Division of Nuclear Medicine, Medical College of Virginia,
Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia

Since the introduction of radionuclides into
clinical medicine, a number of specific tests have been
designed to test thyroid function and to diagnose diseases of the thyroid gland.
These studies can be broadly grouped into in
vivo and in vitro studies. Using 131 1and 1251, tests have
been designed to measure thyroid function at the
hypothalamic, pituitary, or thyroid level and at the
peripheral level by radioimmunoassay or radioassay
of circulating thyroid hormones. The following
schema of testing may be used to assess thyroid function:
I. Hypothalamus. Following the intramuscular administration of thyrotropic-releasing hormone, the following
changes occur in plasma thyroid-stimulating hormone
(TSH) level, which can be measured by radioimmunoassay using 12'1:
CONDITION

I. Normal
2. Hyperthyroidism
A. Toxic Diffuse Goiter
B. Toxic Nodular Goiter
C. Toxic Nodule
3. Hypothyroidism
A. Hypothalamic
B. Pituitary
C. Thyroid

Increased
No change
Increased

11. Pituitary capability of secreting TSH under normal and

abnormal conditions can be accurately measured by determinati on of peripheral level of TSH using 120! radioimmunoassay techniques. The following are TSH values
for various thyroid disorders:

* Presented by Dr. Sharpe at the Postgraduate Course in
Nuclear Medicine, February 27, 1975, in Williamsburg, Virginia.
MCV QUARTERLY 11(2): 75-77, 1975

Normal
Normal
Normal
Increased (I)
Increased (l)
Low
Normal
Increased

III. Assessment of thyroid glandular function can be determined by measuring the concentration of " 1 ! using basal
and dynamic studies following oral administration of 131 1.

I.

BASAL STUDIES

PERCENT

3 hours

131

1 CONCENTRATION

5 hours

24 hours

A. Normal Curve t2.5-l I.6% t4.l-l4.9% t9.0-3l.0%
B. Hyperthyroid
31.0%
14.9%
>ll.6%
Curve
C . Hypothyroid
4.1%
9.0%
< 2.5
Curve

TSH
Increased
No change
No change
No change

TSH
l-lOµU / mlt

CONDITION

I. Normal
2. Hyperthyroidism
A. Toxic Diffuse Goiter
B. Toxic Nodular Goiter
C. Toxic Nodule
D. Hypothalamic
E. Pituitary Tumor
3. Hypothyroidism
A. Hypothalamic
B. Pituitary
C. Thyroid

2.

DY NAM IC STUDIES

A. TSH Stimulation Test
B. T-3 Suppression
C. KClO, Discharge

NORMAL R ESPONSE

> 50% Increase
> 50% Decrease
< 3% Decrease

Determination of the circulating thyroid hormones by radioassay and radioimmunoassay techniques using 125 1 are readily available and offer accurate measurement of these hormones when properly
performed. Normal values for the circulating hormones are as follows:
t Normal values for the Medical College of Virginia.
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l. Total thyroxine
2. Triiodothyronine
3. Serum free thyroxine

5.6-13.lµg / dlt
70-170 ng/ dlf
1.2-3.5 ng/ dlt

Discussion. Differential diagnosis of diseases of
the thyroid can be made with a high degree of certainty using the previously mentioned tests employing radionuclides. The clinical applicability of the
various tests is dependent upon a thorough knowledge of thyroid physiology and interrelationships of
trophic hormones and carrier proteins. A review of
the disease states and diagnosis using specific tests
follows.
l. Hyperthyroidism. The vast majority of cases
can be diagnosed on clinical grounds alone from the
history and physical findings. Confirmation is easily
obtained by employing the 1311 uptake at 3, 5, and 24
hours. This will be elevated in the majority of
hyperthyroid patients. The above-mentioned test in
conjunction with the T-4 and serum free thyroxine
(SFT)-4, which are usually elevated, will establish the
diagnosis in both Graves' disease and hyperthyroidism
due to a nodular goiter. If the diagnosis is suspected
on clinical grounds and the above tests are normal,
one can then perform the T-3 suppression study. This
is done by obtaining a baseline uptake at 3, 5, and 24
hours and then placing the patient on Ltriiodothyronine, l 50µg daily for seven days. The uptake in the normal person is suppressed after T-3 administration by at least 50% and is usually below 20%
at 24 hours. Hyperthyroid patients seldom suppress
below 20% and never below 50% of original uptake.
The usual hyperthyroid patient has little or no change
in 24-hour uptake following T-3. Data from our
laboratory on T-4 and SFT-4 also reveal less than
50% suppression in the hyperthyroid patient with the
average change being lµg/ dl or less. In rare cases,
tl1yrotoxicosis may be due to elevated T-3 levels.
Under these circumstances, the T-4 and SFT-4 and
uptake are normal but the latter is nonsuppressible.
2. Hypothyroidism. In contrast to hyperthyroidism, hypothyroidism is not always easy to diagnose.
This disease has protean manifestations and may be
insidious in onset.
Diagnosis when hypothyroidism is suspected
clinically is best confirmed by a 24-hour 1311 uptake of
less than 9% in 24 hours and a low total and free
thyroxine of less than 5.6µg/ dl and 1.2 ng/ dl, respectively.
Differentiation between pituitary or thyroid
failure can now be made by measuring serum TSH by

125 1 radioimmunoassay following intramuscular or intravenous injection of thyrotropin-releasing hormone
(TRF). A rise in the serum TSH will occur within approximately 15 to 30 minutes after intravenous injection (2) and 2 to 3 hours after intramuscular TRF (3)
injection if the pituitary is intact. Failure to detect a
significant rise in TSH after TRF administration implies pituitary failure and hence, establishing the
diagnosis of secondary hypothyroidism.
3. Subacute thy roiditis. Diagnosis of subacute
thyroiditis is usually suggested by the clinical picture
of anterior neck pain with exacerbation on swallowing or coughing, radiation of pain to the ears,
hoarseness, and signs and symptoms of hypermetabolism. The thyroid is usually enlarged and especially
tender.
Laboratory confirmation is established by the
presence of a low 1311 uptake at 3, 5, and 24 hours and
an elevated T-4 and SFT-4.
4. Enzymatic defects. These are usually characterized by the presence of a goiter dating from early
childhood or the development of thyroid enlargement following ingestion of certain drugs or foods.
Laboratory studies usually demonstrate an
elevated 13 11 uptake value, low total T-4 and SFT-4
and discharge of 131 I from the thyroid gland of greater
than 3% following oral administration of potassium
perchlorate or potassium thiocyanate.
5. Nodules. Adequate assessment of both single
and multiple nodules in the thyroid gland require that
a scan be performed after the administration of 1311
(4), 1251 (5) if available, or 99mTc (6). The former is
performed in our laboratory. Evaluation of nonfunctioning nodules subsequently removed surgically at
our institution over a ten-year period reveals that
single nonfunctioning nodules were malignant in
12.5% of cases, multiple nodules in 16.5%, with the
total overall incidence of malignancy being 13.0% in
nonfunctioning nodules. (These findings have been
noted in a study by J. M . Harrison, MD, R . H .
Kirkland, MD , and the author, unpublished data).
Or 24 malignant nodules out of 184 nonfunctioning nodules by scan.
The incidence of malignancy in hot nodules in
the same study was 1 out of 74, or 1.3%. Reexamination of the scan in the one case revealed that, in
retrospect, this most likely was a cold nodule. A
functioning nodule is thus strong evidence against
malignancy, although some reports of this occurring
have appeared in the literature (7).
The autonomous nodule with or without
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hyperthyroidism is characterized by uptake in the
nodule only and suppression of the remaining thyroid
tissue. The nodule fails to suppress following the administration of L-triiodothyronine as previously discussed and there is no significant change in the T-4 or
SFT-4 by 1251 radioassay. Thyroid-stimulating hormone and long-acting thyroid stimulator (LA TS)
values are characteristically low for the former and
undetectable for the latter. Autonomy can be confirmed by repeating the scan after administration of
10 units of TSH.
Conclusion. Correct assessment of thyroid function and evaluation of nodules can be obtained by the
proper application of the appropriate in vivo or in
vitro tests as previously discussed. Thyroid function
can now be evaluated at the hypothalamic, pituitary,
and thyroid level using both 131 1 and 1261 and at the
peripheral level using 1261 radioassay or radioimmunoassay procedures. Using these procedures as
described, quantitative evaluation of thyroid function
can be made, and in most instances the disease
process can be defined in a specific manner.
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Evaluation of Thyroid Nodules-Hot and Cold*
MELVIN J. FRATKIN, M.D.
Assistant Professor, Departments of Radiology and Medicine, Medical College of Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia

Thyroid nodules occur frequently, are more
common in women, and the incidence increases with
age for both sexes. Clinically normal thyroid glands
commonly contain nodules in autopsy series. In
20- to 50-year-old females, as high as 50% of the
thyroid glands are nodular, whereas in males the
incidence approaches 30% (1 ). When the prevalence of clinically palpable thyroid nodules was the
objective of the Framingham population researchers,
Vander et al (2) detected nodules in 6.4% of females
and 1.5% of males aged 30-50 years. Even with
diligent, thorough examination of the neck, only
about one tenth of pathologically nodular thyroid
glands can be detected. However, the number of
palpable nodules is significant, and determination of
the pathology of the nodule or goiter, once found,
rests with the patient's physician. Unfortunately, a
detailed history and physical examination frequently
does not provide all the necessary information
needed to make a definite etiologic or pathologic
diagnosis. Knowledge of the type of goiter is mandatory for proper treatment of the various disorders
of the thyroid gland.
The various types or causes of goiters are shown
in Table l. Goiters may be divided clinically into
diffuse or nodular; hyperthyroid, euthyroid, or
hypothyroid. It is readily apparent that several
pathologic entities may be diffuse or nodular in addition to altering thyroid function. Hyperthyroid
patients may have a diffuse goiter, solitary nodule, or
a multinodular gland. Graves' disease usually presents no diagnostic problems, but, rarely, a toxic

* Presented by Dr. Fratkin at the Postgraduate Course in
Nuclear Medicine, February 27, 1975, in Williamsburg, Virginia.
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diffuse goiter may be caused by excessive pituitary
thyroid-stimulating hormone (TSH) from hypothalamic thyrotropin-releasing hormone (TRH)
stimulation or pituitary tumor. Subacute nonsuppurative thyroiditis may be focal or diffuse and cause
transitory hyperthyroidism. The hyperthyroid phase
of this disease is associated with a low or blocked
radioactive iodine uptake (RAIU) and usually a painful, hard gland. The hyperthyroid adenomatous
goiter produces the usual findings of thyrotoxicosis
and, clinically, a multinodular goiter. Evaluation of a
toxic adenoma will be discussed later.
Euthyroid diffuse goiters, with the exception of
thyroiditis, represent compensatory enlargement of
the gland in an attempt to maintain normal hormone
production. Patients with dietary iodine deficiency
have an elevated RAIU that is suppressible with
supraphysiologic doses of thyroid hormone (our
standard procedure is to give l 50µg daily of
triiodothyronine for seven days). Excessive iodine intake is associated with a suppressed or blocked
RAIU. Diffuse goiter from congenital thyroidal enzyme deficiency, that is, peroxidase deficiency, results
in an initially elevated RAIU with discharge of
radioiodine from the gland following potassium
perchlorate administration. The early adenomatous
goiter often feels diffuse rather than nodular. The
RAIU usually is normal, but the scan often shows
nonuniform distribution of radioactivity within the
gland. Subacute thyroiditis may diffusely involve the
gland, and the patient may be euthyroid when seen.
Chronic thyroiditis (Hashimoto's thyroiditis) is a
painless, firm goiter frequently with high titers of antithyroid antibodies present in the serum. Any of the
diffuse goiters may be accompanied by hypothyroidism, but low thyroid function is more comMCV QUARTERLY 11(2): 78-83, 1975
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TABLE 1
Types of Goiters
DIFFUSE

NODULAR
HYPERTHYROID

Graves' Disease
Excess TSH
Thyroiditis

Adenomatous
Adenoma
Thyroiditis
EUTHYROID

Iodine Deficiency
Iodine Excess
Enzymatic Defects*
Adenomatous
Thyroiditis*

~arcinoma

Aden om a
Colloid Cyst
Adenomatous
Thyroiditis

* May be associated with hypothyroidism

manly seen with congenital enzymatic deficiency
goiters and Hashimoto's thyroiditis.
Patients with nodular goiter (as mentioned
earlier) may be hyperthyroid or, rarely, hypothyroid,
but are usually eµthyroid. The euthyroid patients
with nodular goiter, and especially those with a
solitary nodule, represent the greatest diagnostic
problem, for thyroid carcinoma must always be considered and excluded. Since one cannot differentiate a
benign from a malignant tumor with certainty by
palpation alone, further diagnostic tests are indicated
(Fig. 1). The thyroid scan will determine whether the
nodule is functioning (Fig. 2) or nonfunctioning (Fig.
3). The pathology of functioning (hot) and nonfunctioning (cold) nodules is shown in Table 2. The
demonstration of a hot nodule with scanning essentially excludes the probability that the lesion is a carcinoma. However, if the nodule is cold, one can only
make a statistical guess concerning the pathology.
Further diagnostic work-up can be pursued prior to
surgical exploration (Fig. 1). Nonfunctioning,
solitary nodules may be separated into cystic and
solid with ultrasonography, and recent reports (3, 4)
suggest that cystic thyroid nodules represent 20% of
cold nodules and are benign. Additional procedures
have been performed in an attempt to non-invasively
exclude thyroid carcinoma. Sonography (5), in addition to distinguishing cystic from solid lesions,
demonstrates a characteristic echo pattern in
malignancy that may prove to be diagnostic if substantiated by additional reports. Thyroid scanning of
cold nodules with other radiopharmaceuticals such as
67 Ga-citrate (6) and 75 Selenomethionine (7, 8) may be
positive in cases of thyroid cancer, but false negatives
( 67 Ga) and
false positives (7 5 Se) are frequent.
Thermography (9) has been tried, but the number

of lesions studied are too few to reach any conclusions. According to an oral communication
from J. Frable, MD, in January, 1975, thin-bore needle aspiration can yield a positive diagnosis of papiflary adenocarcinoma, but cannot differentiate follicular adenoma from adenocarcinoma. I might sum
up by saying that the solitary, nonfunctioning and especially the solid thyroid nodule is malignant until
proven otherwise by surgical exploration, The results
of sonography are exciting and promising, but
further studies are indicated before the role of
ultrasound can be established in the evaluation of
thyroid nodules (Fig. 4).
The thyroid nodule that concentrates radioiodine may be a follicular adenoma, adenomatous
nodule, normal thyroid tissue such as a lingual thyroid, or residual hyperplastic thyroid tissue following
a subtotal thyroidectomy. The triiodothyronine suppression test will differentiate the autonomously functioning thyroid nodule from other types of functioning nodules (Fig. 5). Treatment of suppressible
functioning thyroid nodules with thyroid hormone
results usually in no further enlargement and frequently in disappearance clinically of the nodule.
The typical autonomously functioning thyroid
nodule is illustrated in Figure 2. Although the patient
is euthyroid, the nodule has suppressed the function
of the normal thyroid tissue and is not suppressible
with administration of triiodothyronine (Cytomel®).
Administration of thyroid-stimulating hormone, 10
units daily for three days, may be used to
demonstrate the presence of normal but suppressed
thyroid tissue. Treatment with 25 millicuries of
radioactive iodine resulted in ablation of the nodule,
appearance of the previously suppressed normal
thyroid gland, and continuation of a euthyroid state.
EVALUATION OF THYROID NODULES
DIAGNOSTIC APPROACH
THYRO ID NODULE

FUNCTIONlt..JG
!c*MEd
SUPPRE SSED

NON-FUNCTIONI NG
SONOGRAPHY

NON-SUPPRESSED

SOLID

CYSTIC

Fig. I-Sequential diagnostic approach in evaluation of thyroid
nodules.

80

FRA TKIN: EVALUATION OF THYROID NODULES

I I
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~

I

Pre - Treatment

·.

LC

Post Treatment

6- 20-73

II - 26- 73

Fig. 2-left. Functioning 4 X 3 cm right thyroid nodule with normal RAIU and serum free thyroxine concentration; no radioiodine
uptake in area of left lobe. Center. Triiodothyronine (T-3) administration produced no decrease in RAIU or nodule uptake. Righi.
Following radioiodine treatment, nodule has been ablated; right and left lobes concentrate radioiodine; overall thyroid function remains
normal.

..

"

The question arises, though, should a nontoxic,
autonomously functioning nodule be treated at all?
What is the natural history of a functioning follicular
adenoma? There are case reports of nontoxic nodules
progressing to toxic nodules which then require
treatment because of the development of clinical
hyperthyroidism. Such a course of events is shown
in Figure 6. Patient W.W. first noted a goiter 15 years
ago, but was advised that no treatment was necessary.
In 1969, his protein-bound iodine (PBI) was normal,
and his nodule had gradually increased in size.
When seen in 1973, he was hyperthyroid. Treatment
with radioiodine achieved a euthyroid state but little
to no reduction in the size of the nodule. It can be
assumed that he had an autonomously functioning
nodule from the onset that progressed in size over the
years, achieving a sufficient mass to produce excessive amounts of thyroid hormone and hyperthyroidism.
TABLE 2
Pathology of Thyroid Nodules
FUNCTIONING

.
Fig. 3-Nonfunctioning thyroid nodule in lower pole of right
lobe. Pathologic diagnosis was follicular adenoma.

HISTOLOGIC DIAGNOSIS

Adenomatous
Adenoma
Carcinoma
Hyperplasia
Thyroiditis, Chronic
Unclassified
Total

NONFUNCTIONING

No.

PERCENT

No.

PERCENT

53

70
15
0
7
0
8

107
31
24
0
7
.J2
184

58
17
13
0
4
8

II

0
5
0
....§
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EVALUATION OF THYROID NODULES
APPROACH TO TREATMENT

EVALUATION OF THYROID NODULES
APPROACH TO TREATMENT

I

I

NON-FUNCTIONING THYROID NODULE

FUNCTIONING THYROID NODULE

I SONOGRAPHY I

c ........._~-.L.I

T3 SUPPRESSION TEST
150µg/d x 7 d

so

CY STI
---ii•• LID*
Rx: ASPIRATION +
Rx: SURGERY+
THYROID HORMONE
THYROID HORMONE

1

SUPPRESSIBLE -----NON-SUPPRESSIBLE
Rx: THYROID HORMONE

*FURTHER EVALUATION OF NON-FUNCTIONING, SOLID
THYROID NODULE IS INVESTIGATIONAL (1975)

Fig. 4-Role of sonography in therapeutic approach to nonfunctioning thyroid nodules.

Is this case the exception or the rule? Horst and
associates (IO) and later Ferraz et al (11) suggest that
the natural history of a nontoxic but autonomously
functioning thyroid nodule is one of progression to
hyperthyroidism. They based their conclusions on
data demonstrating toxic nodules being larger than
nontoxic ones, and the rather continuous spectrum of
functional activity from euthyroidism to overt
hyperthyroidism. Similarly, Hamburger and Meier
(12) noted that those patients who were hyperthyroid

Rx:

TOXIC
1311

NON-TOXIC
Rx: 131 I

SURGERY
OBSERVATION
Fig. 5-Diagnostic and therapeutic approach to functioning
thyroid nodule.

were older and had larger nodules than euthyroid
patients with nonsuppressible functioning nodules. In
their prospective study of 28 nontoxic patients with
autonomously functioning nodules followed one to
ten years (majority followed less than six years), none
became hyperthyroid, but four glands increased in
size. A retrospective study by McCormack and
Sheline ( 13) revealed 1 out of 14 nontoxic untreated
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Fig. 6-Left . Large 9 X 6 cm toxic nodule with high RAIU and serum free thyroxine concentration. Right. Establishment of normal
function, but persistence of nodule following radioiodine treatment.
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Fig. 7-Left. Functioning thyroid nodule in lower right lobe with partial suppression of the remainder of the gland. Right. Loss of function
in outlined nodule.

patients developed hyperthyroidism. The longest
follow-up was 8 \/2 years with a mean of about 4 years.
The available data suggest circumstantially that nontoxic, autonomously functioning thyroid nodules
progress to toxicity, but usually not within the first
eight to ten years from the initial diagnosis.
The next case (Fig. 7) illustrates the opposite
natural history-spontaneous disappearance of function from a hot nodule. The initial scan shows a functioning nodule with partial suppression of the
remaining gland. Treatment with triiodothyronine,
l 50µg daily for seven days, resulted in a RAIU of I%,
and no specific therapy was instituted. The patient
became concerned about the small but visible mass in
her neck. When she returned nine months later, the
nodule had lost its ability to take up radioiodine.
Surgical exploration revealed a follicular adenoma.
Our experience and that of others (10, 13) reveal

that large doses of radioiodine (20-40 millicuries) are
necessary to ablate autonomously functioning
thyroid nodules, that euthyroid function is achieved,
and that hypothyroidism does not develop following
treatment when the normal thyroid tissue is protected
by endogenous and/ or exogenous thyroid hormone.
On occasion, a residual but nonfunctioning nodule
may persist following radioiodine therapy. Surgery,
although equally effective therapy (13), adds unnecessary additional cost and morbidity for the patient
with an autonomously functioning thyroid nodule.
In summary, functioning but suppressible
thyroid nodules may be treated successfully with
thyroid hormone (Fig. 5). Completely or partially
autonomously functioning nodules are benign follicular adenomas. This type of nodule may progress
in size to produce hyperthyroidism or may lose its
ability to concentrate iodine. Radioiodine is a safe,
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efficient treatment for autonomously functioning
thyroid nodules and should be considered the treatment of choice.

83

7. THOMAS CG JR, PEPPER FD, OWEN J: Differentiation of
malignant from benign lesions of the thyroid gland using complementary scanning with "selenomethionine and radioiodide.
Ann Surg 170:396-408, 1969.

REFERENCES
l. MORTENSEN JD, WOOLNER LB. BENNETT w A: Gross and
microscopic findings in clinically normal thyroid glands. J Clin
Endocrinol Metab 15:1270-1280, 1955.

2. VANDER JB, GASTON EA. DAWBER TR: The significance of
nontoxic thyroid nodules. Ann Intern Med 69:537-540, 1968.
3. BLUM M , GOLDMAN AB, HERSKOVIC A, ET AL: Clinical applications of thyroid echography. N Engl J Med 287:1164-1169,
1972.

8. WEINSTEIN MB, ASHKAR FS, CARON CD: " Se Selenomethionine as a scanning agent for the differential diagnosis of the
cold thyroid nodule. Semin Nuc/ Med 1:390-396, 1971.
9. SAMUELS Bl: Thermography: a valuable tool in the detection of
thyroid disease. Radiology 102:59-62, 1972.
10. HORST w, ROSLER H, SCHNEIDER c, ET AL: 306 cases of toxic
adenoma: clinical aspects, findings in radioiodine diagnostics,
radiochromotography and histology; results of 111 1 and surgical treatment. J Nuc/ Med 8:515-528, 1967.

4. MISKIN M, ROSEN IB, WALFISH PG: B-mode ultrasonography
in assessment of thyroid gland lesions. Ann Intern Med
79:505-510, 1973.

l l. FERRAZ A, MEDEIROS-NETO GA, TOLEDO AC. ET AL:
Autonomous thyroid nodules: I. A Clinical classification and
the use of a diagnostic index. J Nuc/ Med 13(pt 2):733-737,
1972.

5. CROCKER EF, M CLAUGHLIN AF, KO SSOFF G , ET AL: The
gray scale echographic appearance of thyroid malignancy. J
Clin Ultrasound 2:305-306, 1974.

12. HAMBURGER JI, MEIER DA: Nontoxic autonomously functioning thyroid adenomata-therapeutic considerations, abstracted. J Nuc/ Med 14:404, 1973.

6. KAPLAN WD, HOLMAN BL, SELENKOW, H. A. , ET AL: 07 Gacitrate and the nonfunctioning thyroid nodule. J Nuc/ Med
15(pt 1):424-427, 1974.

13. M c CORMACK KR, SHELINE GE: Long-term studies of solitary autonomous thyroid nodules. J Nuc/ Med 8:701-708,
1967.

The Diagnosis and Treatment of
Carcinoma of the Thyroid*
RICHARD H. KIRKLAND, M.D.

Professor of Medicine, Medical College of Virginia, Health Sciences Division,
Virginia Commonwealth University, Richmond

Before going into a discussion of the diagnosis
and treatment of carcinoma of the thyroid, I would
like to make a few observations on the means of
detection.
Thyroid scanning, in my opinion, is useful only
in the study of nodules. We see many patients who
have had scans for diffuse thyroid enlargement, and I
feel that in this instance, scans are useless. The basic
reason for the scan is to discover which pieces of
thyroid tissue have to be removed because of possible
malignancy. I would like to emphasize, that the
physician has to do the scan himself. He has to
localize the nodule, properly mark it on the scan, and
remain during the scan, as the patient may move his
neck, thus moving the position of the nodule in
reference to the marks. We have seen scans in the
early days of isotope scanning where the technician,
who was not taught to palpate the thyroid, marked
the scan. This system is inadequate, as errors can occur.
Using the T-3 suppression test, the criteria for
suppression is a fall in uptake below 20% in 24 hours
after a week on T-3, 150µ daily. However, the normal
uptake is often below 20%, and hyperthyroid patients
may also have less than 20% uptake, so the test is losing some of its specificity. I think the criteria for the
suppression test should be changed, or the interpretation of it, to indicate that there is "no significant" fall
in uptake after T-3 for a week. It is very difficult to establish such criteria, because I do not know what normal figures to give. We recently saw a patient with a

* The following

is an edited transcription of a lecture presented by
Dr. Kirkland at the Postgraduate Course in Nuclear Medicine,
February 27, 1975, in Williamsburg, Virginia .
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nodule who had 8% uptake in 24 hours prior to T-3.
We went ahead with T-3 suppression, and he had 7%
after T-3. We did not know what to do or how to interpret this. We treated the patient with radioactive
iodine, thinking that the nodule was not suppressible,
and the other lobe did reappear on later scanning.
This patient had an autonomous nodule with an 8.0%
uptake.
In my opinion, 3- and 5-hour uptakes are absolutely essential. I would not want an uptake run
only at 24-hour intervals, because we do see patients
who have taken iodides or, unknown to us, antithyroid drugs and who have normal 24-hour uptakes but who have blocked thyroid function and are
not making thyroid hormone at the moment.
Therefore, it is necessary to run 3- and 5-hour uptakes to identify this blocked type of function and, if
diagnosis is not clear at that time, at a later 24-hour
point.
In the hot nodule with low radioiodine uptake
where the T-3 suppression test may not be of great
value, one can give TSH and do a scan afterward to
see if the other lobe reappears. If it does reappear, indications are that the nodule is an autonomous one
which was suppressing TSH.
I now want to discuss the diagnosis and treatment of carcinoma of the thyroid. Carcinoma of the
thyroid gland is both rare and common. It is a frequent diagnosis on pathological sections, but clinically it is a rare disease. Very few patients die from
carcinoma of the thyroid. Each of us has seen so few
thyroid carcinomas of clinical significance that it is
difficult to gather a series sufficiently large to determine what treatment techniques are best. As some
MCV QUARTERLY l 1(2): 84-88, 1975
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evidence of the incidence, Dr. Fratkin showed that in
one hundred cases of thyroid nodules 70% were cold.
Of the 70% that were cold, he said 15% were carcinomatotis. That is a high incidence of carcinoma of
the thyroid. Recently, a student and I went around on
the wards at the Medical College of Virginia and felt
every patient's thyroid regardless of what the patient
had been admitted for. Thirty-three percent of the
women incidentally had palpable nodular thyroid
disease. If we take these female patients with
nodules-70% of them cold and 15% of them with
carcinoma-3.48% of women in the Medical College
of Virginia should have carcinoma of the thyroid .
Obviously these figures are not true clinically. Even
the pathologist has problems in diagnosing thyroid
malignancy. Thyroid-stimulating hormone stimulation of the thyroid makes it so hypertrophic that
sometimes the thyroid looks malignant although it
doesn't behave that way.
In patients with carcinoma of the thyroid, the
natural course of the disease is variable, so that a
long-term follow-up is necessary to determine what
happens to them. One cell type, such as papillary carcinoma of the thyroid, might change to follicular, or
the metastases may show at the same time different
pathological types. Any treatment I propose,
therefore, would have to be very arbitrary.
I would like to mention something about the
etiology of the carcinoma of the thyroid. Two
Australians, Purves and Geishbach, in 1948, gave rats
thiourea for two of their three-year life spans and
found that 100% of the rats developed carcinoma of
the thyroid. (This fact does not stop us from giving
propylthiouracil to patients, and some clinics advocate this as the best treatment for
hyperthyroidism). They stated in their article, "We
think that the administration of thyroid extract to
these rats would have prevented this." They gave
thiourea to rats after. hypophysectomies and none of
these animals developed carcinoma of the thyroid .
This suggests to me that the etiology for the carcinoma, or an etiological factor, was the TSH level
which rose in the thiourea-treated rats and stimulated
a blocked gland. That was the first finding that led me
to think that carcinoma might be produced by longterm TSH stimulation of a blocked or damaged
thyroid gland. There is also an increased incidence of
carcinoma of the thyroid in patients who have congenital enzyme blocks. One type of congenital enzyme block is followed by nearly 100% incidence of
carcinoma of the thyroid-another fact that makes

me think that TSH stimulation might lead to carcinoma. There is a higher incidence of carcinoma of
the thyroid in thyroiditis where the gland may be injured. The TSH may rise and the same circumstances
occur. Irradiation of the neck in childhood is another
etiologic factor. There are also cases of thyroid carcinoma which are TSH dependent. These tumors
tend to grow more rapidly if the TSH levels are high.
We should, therefore, keep the TSH low in patients
who have carcinoma of the thyroid. This concept has
been an important influence in my treatment of
thyroid patients. Once hyperthyroidism is eliminated,
I think anyone with thyroid disease should be on
long-term suppressive thyroid hormones.
These factors led me to review the histories of
patients with carcinoma of the thyroid at the Medical
College of Virginia in order to see if I could find a
thyroid-damaging factor. Fifty percent of the patients
had had some thyroid destructive disease, such as
thyroiditis or colloid goiter, or treatment for thyroid
suppression, such as surgery. None of them had had
radioiodine therapy, but I think the incidence of carcinoma of the thyroid might increase after radioiodine if we live long enough to observe this course.
How do we diagnose the carcinoma of the
thyroid? Most cases are not diagnosed by symptoms,
although there are some symptoms, such as
hoarseness or a tracheal narrowing shown on AP and
lateral x-rays. Hoarseness suggests that the recurrent
laryngeal nerves might be invaded, and this might indicate the possibility of carcinoma, especially if it is
accompanied by a mass in the thyroid area.
Dysphagia is suspicious. X-ray studies of the esophagus showing real obstruction are helpful and do
suggest that there is true disease present and not just
an anxiety globus hystericus. We recently noted a
bruit over the thyroid gland in the absence of
hyperthyroidism. This indicated that there was high
vascularity and suggested the possibility of

Thyroid
Pathology found in "hot" nodules
Nodular colloid goiter
Hyperplastic goiter
Aden om a
Carcinoma
Unclassified

Fig. I-Pathology in "hot" nodules at MCV.
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Pathology found in cold nodules ( 184)

+

58%
4%
17%
13%
8%

Nodular colloid goiter
Chronic thyroiditis
Adenoma
Carcinoma
Unclassified

TCN

Fig. 2-i>athology is 184 cold nodules at MCV.

malignancy. A distant metastasis might be a hint of
carcinoma of the thyroid. If there are nodules, we
want to do scans. If the scan shows a cold nodule,
carcinoma is a prime possibility. Figure 1 shows the
pathology we have seen in our "hot" nodules.
Nodular colloid goiter was found in 70% of cases,
hyperplastic goiter (we are not sure what the
pathologist meant by this as these were supposedly
nontoxic patients) in 15%, adenoma in 15%, but no
carcinoma. Figure 2 shows the pathology in 184 cold
nodules which were removed . Thirteen percent were
carcinomas of the thyroid.

~'

Posterior
.. ... ; "' . , .
~

I

'-

'f

>1- TCN

Anterior

•

h. Lot.

SSN

Harris

Fig. 4-0blique scan of saii-ie patient, revealing cold nodule.

.
~·

t

......... .............
.._....._
. .._.
......_,....._...
........... .

Rt.

·'·.... .

•

r·u

.

..

•

Lt

...._._._

,

;/

AP_

Horris

'

---~.
•••
•

~,

~

, ,ssN

Fig. 3-AP scan of patient with suspect nodule.

I want to emphasize the importance of lateral
scans. Figure 3 is an AP scan of a patient who had
had a nodule. One might think that this was a functional nodule and not malignant. But on the lateral or
oblique scan (Fig. 4), a cold nodule is seen in front of
the radioactivity. Figure 5 shows a nodule that might
be interpreted as a hot nodule. There is suspicion that
it might not be a hot nodule, however, for the center
of the gland is thicker, and one would think it would
have a higher radioactivity. On the lateral scan, it is
confirmed as a cold nodule .
The treatment of carcinoma of the thyroid varies
with the cell type, and Figure 6 sHows the main types
of the disease. The first approach to treatment of carcinoma of the thyroid is surgery. The extent of the
surgery depends on the type of lesion. A biopsy with
a frozen section will indicate what type of malignancy
one is dealing with. The nodule should be removed
along with any suspect tissue, and if it is carcinoma
on a frozen section, a total thyroidectomy is indicated. The only exception would be that I would
ask the surgeon not to take the parathyroid glands.
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As this might be difficult, he would perform a nearly
total thyroidectomy. Myxedema as a result of surgery
is of no concern because the patient will be placed on
thyroid extract. All patients with carcinoma of the
thyroid should be on thyroid extract for the rest of
their lives in the hope that hormonal suppression of
the tumor will be achieved, just as one might treat
carcinoma of the breast with appropriate hormonal
treatment. Radical neck dissection is not often my
choice. The surgeon usually decides this. If he feels
that the nodes are within the range of surgical resection, he should try to get them out, but in my opinion, severely disfiguring, radical neck dissection is of
no great value. The prognosis for carcinoma of the
thyroid is so good that, other than for anaplastic
types, I would not urge extensive neck dissection. In a
medullary carcinoma, there is one follow-up technique
and that is to check on calcitonin levels, because
this offers a marker for continuing disease. If the
calcitonin levels were high before removal and

afterwards fell to normal, it would be very reassuring
that the malignancy had been completely removed. If
calcitonin levels rose in the future, they would indicate that the carcinoma had recurred and that
further treatment should be considered.
There is a difference of opinion regarding the
surgical follow-up schedule. Some authors would
wait a month and do a radioactive iodine uptake

Classification of Thyroid Neoplasms
A. Adenoma
B. Carcinoma
1. Adenoma malignum
2. Papillary
3. Follicular
4. Medullary
5. Anaplastic
Fig. 6-Main types of thyroid disease.
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study to see if there is any residual thyroid tissue in
the neck. They would ablate it with radioactive iodine
and put the patient on thyroid hormone while waiting
to see whether the patient develops further disease.
This seems to me unnecessary as the patient may have
already been cured. I would put the patient on
thyroid hormone after the initial thyroidectomy and
wait. If disease appears, I would stop the thyroid
replacement and do a 131 1 scan. If there is uptake of
131 1 in the residual thyroid area, a thyroid ablative
dose of 131 1 should be given. In one to two months, a
tracer dose should be given to see whether there is
any retention of the isotope after 48 hours. At the
Medical College of Virginia, we determine 24- and
48-hour urinary excretions of 1311 at that stage, and if
there is any significant retention (if the patient excretes less than 90% of the radioiodine in the urine in
48 hours), we scan the whole body searching for areas
of retention and treat with large doses of radioiodine.
If there were significant retention, we would try to
stimulate maximal uptake of radioactive iodine prior
to treatment by giving TSH intravenously or intramuscularly for three days and repeat the 1311 uptake.
Should there be increasing retention, I would keep up
the TSH for three more days until the maximal uptake
was reached, because this may be the only opportunity
to get an excellent uptake in the tumor. Therefore, I
would continue TSH until I obtained maximum
retention of the tracer dose, then give a large dose of
radioactive iodine (150 millicuries of radioiodine),
hoping to obtain the maximum uptake in the tumor.
After radioiodine had had a chance to accumulate
in the gland, I would put the patient on triiodothyronine (one of the few clinical uses for this

hormone in treatment) in order to suppress TSH in
the interim, while waiting for the effect of the dose.
The patient should be kept on that dose for about six
weeks. The dose should then be discontinued and the
patient retested with radioactive iodine in eight
weeks. As long as there is uptake of radioactive
iodine or retention of the isotope with less than 90%
excretion in 24 hours, I would continue to treat the
patient with radioactive iodine at approximately twomonth intervals until I had no further retention of the
radioactive material. Of course, this has to be
monitored by blood counts, primarily platelet counts.
We have not seen significant platelet reduction until
we have given 300 to 400 millicuries of radioiodine.
Once I had achieved as much radioactive iodine treatment as possible, that is, there was no longer any
retention of the isotope 48 hours after a tracer dose, I
would put the patient on totally suppressive and
replacement doses of levothyroxine or triiodothyronine. The triiodothyronine is used because it
can be stopped more quickly, and its effect disappears
more quickly. An additional method of treatment
to consider, when radioactive treatment was no
longer effective, would be x-ray therapy to any areas
that were causing symptoms.
The major point I would like to make is that we
should try to prevent thyroid carcinoma by administration of thyroid hormones to all patients with
potentially high TSH and damaged-thyroid disease,
using suppressive doses of levothyroxine. In my opinion, all patients who have thyroid disease should be
treated with thyroid hormone indefinitely, once
hyperthyroidism has been eliminated.
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Excerpted from Volume 2
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Serles
on physical examination
of the abdomen:

Normally palpable organs:
the edge of the liver descending ,
on inspiration, below the costal
margin (Al: the lower pole of the
right kidney (BJ; the abdominal
aorta (CJ: the descending colon
and the sigmoid (DJ: the ascending colon (El: and occasionally
the bladder (though rising of
this organ beyond the pubis
does not necessarily indicate
disease).
Impossible to outline, unless
diseased, distended or enlarged:
the gallbladder, pancreas,
stomach, small in testine, transverse colon and spleen.
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The A . H . Robins GI. Series con sists of six book- ,,
- ·
lets. designed to provide a Quick, yet comprehen- :
1 •
sive review of basic procedures and practices in
G .I. medicine - with particular emphasis on the
physical examination as performed in the office o r
::c~
at bedside. If you have teaching responsibilities.
-,.
limited qua ntities a re available: Part 1 - lnspect10n.
Part 2-Palpation , Part 3-Percussion. Part 4 - Auscultation. Part 5 Abdominal Pain and Part 6 - Different1al Diagnosis of Abdominal
D isorders. Write to: The Medical Department , A.H . Robins Company.
1407 C ummings Drive. Ric hmond . Virginia 23220 .
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Normally palpable organs:
the edge of the liver descending ,
on inspiration, below the costal
margin (A) ; the lower pole of the
right kidney (BJ; the abdomi nal
aorta (CJ; the descending colon
and the sigmoid (DJ; th e ascending colon (E); and occasionally
the bladder (though rising of
this organ beyon d the pubis
does not necessarily indicate
disease).
Impossible to outline, unless
diseased , distended or enlarged:
the gallbladder, pancreas,
stomach, small intestine, transverse colo n and spleen.
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B.rief summary. Adverse Reactions: Blurring of vision. dry mouth.
d1ff1cult urination , and flushing or dryness of the skin may occur
on higher dosage levels. rarely on usual dosage. Contraind1cat1ons: Glaucoma; renal or hepatic disease. obstructive uropathy
(for example, bladder .n.eck obstruction due to prostatic hypertrophy); or hypersens1t1v1ty to any of the ingredients.
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Brief summary. Adverse Reactions: Blurring of vision, dry mouth.
difficult urination, and flushing or dryness of the skin may occur
on higher dosage levels. rarely on usual dosage. Contraindications: Glaucoma; renal or hepatic disease. obstructive uropathy
(for example, bladder neck obstruction due to prostatic hypertrophy); or hypersensit1v1ty to any of the ingredients.
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Before prescribing, please consult
complete product information, a summary of which follows:
Indications: Tension and anxiety

states, somatic complaints which are .
concomitants of emotional factors; psychoneurotic states manifested by tension,
anxiety, apprehension, fatigue, depressive symptoms or agitation; symptomatic
relief of acute agitation, tremor, delirium
tremens and hallucinosis due to acute
alcohol withdrawal; adjunctively in skeletal muscle spasm due to reflex spasm to
local pathology, spasticity caused by
upper motor neuron disorders, athetosis,
stiff-man syndrome, convulsive disorders
(not for sole therapy).
Contraindicated: Known hypersensitivity to the drug. Children under 6
months of age. Acute narrow angle glaucoma; may be used in patients with open
angle glaucoma who are receiving appropriate therapy.
Warnings: Not of value in psychotic
patients. Caution against hazardous
occupations requiring complete mental
alertness. When used adjunctively in convulsive disorders, possibility of increase
in frequency and/ or severity of grand mal
seizures may require increased dosage of
standard anticonvulsant medication;
,,,,,,£.....,=---<_,.
abrupt withdrawal may be associated
with temporary increase in frequency
and/ or severity of seizures. Advise
against simultaneous ingestion of alcohol
and other CNS depressants. Withdrawal
symptoms (similar to those with barbiturates and alcohol) have occurred following abrupt discontinuance (convulsions,
tremor, abdominal and muscle cramps,
vomiting and sweating). Keep addictionprone individuals under careful surveillance because of their predisposition to
habituation and dependence. In pregnancy, lactation or women of childbearing
age, weigh potential benefit against
possible hazard.
Precautions: If combined with other
psychotropics or ant icon vu lsants, consider carefully pharmacology of agents
employed; drugs such as phenothiazines,
narcotics, barbiturates, MAO inhibitors
and other antidepressants may potentiate
its action. Usual precautions indicated in
patients severely depressed, or with latent
depression, or with suicidal tendencies.
Observe usual precautions in impaired
renal or hepatic function. Limit dosage to
smallest effective amount in elderly and
debilitated to preclude ataxia or oversedation.
Side Effects: Drowsiness, confusion,
diplopia, hypotension, changes in libido,
nausea, fatigue, depression, dysarthria,
jaundice, skin rash, ataxia, constipation,
headache, incontinence, changes in salivation, slurred speech, tremor, vertigo,
urinary retention, blurred vision. Paradoxical reactions such as acute hyperexcited states, anxiety, hallucinations,
increased muscle spasticity, insomnia,
rage, sleep disturbances, stimulation
have been reported; should these occur,
discontinue drug. Isolated reports of neutropenia, jaundice; periodic blood counts
and liver function tests advisable during
long-term therapy.

When, for example, despite counseling,
tension and anxiety continue to produce
distressing somatic symptoms
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